Design Therapeutics
DSGN
87 hedge funds and large institutions have $77.6M invested in Design Therapeutics in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 38 reducing their positions, and 24 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 97 → 87 (-10)
10.62% less ownership
Funds ownership: 69.32% → 58.7% (-11%)
12% less call options, than puts
Call options by funds: $263K | Put options by funds: $299K
29% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 38
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
68% less capital invested
Capital invested by funds: $244M → $77.6M (-$167M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$10.4M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.3M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$5.61M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.78M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$4.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$32.4M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$22.1M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$18.7M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$5.23M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.16M |
DSGN Hedge Fund Activity: Q3 2023 in Review
87 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q3 2023, worth a combined $77.6M — down 68% from $244M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of DSGN and 14 opened new positions — a net loss of 10 holders — while 38 trimmed existing stakes and 27 added.
The largest buyer was Logos Global Management, adding an estimated $10.4M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $32.4M sold.
- 87 institutional investors held Design Therapeutics (DSGN) as of Q3 2023, down from 97 in Q2 2023.
- Funds reported $77.6M of Design Therapeutics stock for Q3 2023, down 68% quarter-over-quarter.
- 14 funds opened new Design Therapeutics positions in Q3 2023 and 24 closed out, a net change of -10 holders.
- The largest Design Therapeutics buyer in Q3 2023 was Logos Global Management, an estimated $10.4M added.
- The largest Design Therapeutics seller in Q3 2023 was Cormorant Asset Management, an estimated $32.4M sold.
Based on aggregated 13F filings for Q3 2023.